Vabysmo gains EU approval for retinal vein occlusion: what changes next
Decision brief
Answer first · skim in under a minute
Living with retinal vein occlusion has a new treatment reference point in Europe after Roche’s Vabysmo secured EU approval for macular edema due to RVO. This plan frames the catalyst, the regulatory basis, and the investor implications for BD and analyst readers.
Living with retinal vein occlusion gained a clearer European treatment option after the European Commission approved Roche’s Vabysmo (faricimab) on 30 July 2024 for macular edema secondary to branch or central RVO. This analysis maps the label change, BALATON and COMINO evidence, and what investors still cannot quantify from public filings alone.
Contents10 sections
Key Takeaways
- The European Commission approved Vabysmo for visual impairment due to macular edema secondary to branch or central RVO on 30 July 2024, adding a third EU retinal indication after nAMD and DME.
- EMA’s EPAR lists RVO alongside wet AMD and diabetic macular edema; initial EU marketing authorisation was 15 September 2022.
- Phase 3 BALATON (NCT04740905) and COMINO showed ~16.9-letter gains at week 24, non-inferior to aflibercept in 1,282 patients.
- FDA RVO approval came earlier (26 October 2023); EU payer uptake and real-world share remain unproven in the public sources cited here.
What did the European Commission approve for Vabysmo in RVO?
On 30 July 2024, the European Commission approved Vabysmo for visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), Roche said in a GlobeNewswire release. RVO became the third EU indication after neovascular age-related macular degeneration and diabetic macular edema.
CHMP had adopted a positive opinion recommending the indication extension on 27 June 2024. For BD and investor readers, that sequence is a standard label-expansion catalyst, not a first marketing authorisation.
How does living with retinal vein occlusion change under the EU label?
Living with retinal vein occlusion often means repeated intravitreal anti-VEGF injections to control macular edema and protect central vision. The EMA product page now states Vabysmo is authorised for adults with wet AMD, diabetic macular edema, and macular edema secondary to RVO.
Per the EMA Vabysmo EPAR overview, treatment is given by an experienced retina specialist as an intravitreal injection, typically starting every four weeks before interval adjustment. The medicine must not be used when there is an active eye infection or severe intraocular inflammation.
What did BALATON and COMINO show at 24 weeks?
Two main studies involving 1,282 patients with macular edema caused by RVO showed Vabysmo was at least as effective as aflibercept at improving vision, EMA reports. After 24 weeks (six doses at four-week intervals), average letter gains were about 16.9 for Vabysmo versus 17.5 and 17.3 for aflibercept in the two trials; benefit was maintained to week 72 with adjustable intervals.
- BALATON (branch RVO): NCT04740905 on ClinicalTrials.gov
- COMINO (central RVO): NCT04740931
- Published 24-week results: ~16.9-letter faricimab gains, non-inferior to aflibercept (PubMed 38280653)
How does the EU decision compare with the FDA RVO label?
Genentech announced FDA approval of Vabysmo for macular edema following RVO on 26 October 2023, also citing BALATON and COMINO. Japan’s Ministry of Health, Labour and Welfare approved RVO in March 2024, according to the same EC announcement.
Initial EU marketing authorisation for Vabysmo (nAMD and DME) dated to 15 September 2022. The July 2024 RVO extension therefore completes a multi-year, multi-region retinal franchise build rather than a de novo EU launch.
Commercial and competitive context for analysts
Roche states Vabysmo is available in nearly 100 countries for nAMD and DME, with more than four million doses distributed globally as of the July 2024 release. That figure is company-reported and not an independent audit of RVO share.
Competing anti-VEGF agents already treat RVO macular edema in Europe. Label parity does not automatically equal formulary wins, tender awards, or injection-share shifts. Analysts should separate the regulatory fact (EC approval) from commercial inference until national HTA and claims data appear.
What remains unproven after the EU RVO approval?
Public EMA and company materials do not disclose EU RVO-specific net pricing, country-by-country reimbursement dates, or real-world persistence versus aflibercept after week 72. Ongoing real-world studies such as NCT06439576 (Farseeing) and NCT06680817 (FaReal) may later inform practice patterns, but they do not yet substitute for post-approval utilization data.
Do not treat the ~80 million people Roche cites as affected by nAMD, DME, and RVO combined as an addressable patient pool for Vabysmo RVO alone.
Related NovaPharma coverage
- Vabysmo (faricimab) drug profile
- Retinal vein occlusion disease profile
- Neurocrine Biosciences pipeline update: catalyst watch
Frequently Asked Questions
Is Vabysmo approved for retinal vein occlusion in the EU?
Yes. On 30 July 2024 the European Commission approved Vabysmo (faricimab) for visual impairment due to macular edema secondary to branch or central retinal vein occlusion, as Roche announced via GlobeNewswire.
What trials supported Vabysmo in RVO?
Phase 3 BALATON (NCT04740905) and COMINO enrolled 1,282 patients with macular edema due to RVO. At week 24, faricimab improved best-corrected visual acuity by about 16.9 letters, non-inferior to aflibercept, per EMA and published trial results.
When did the FDA approve Vabysmo for RVO?
The U.S. Food and Drug Administration approved Vabysmo for macular edema following retinal vein occlusion on 26 October 2023, ahead of the July 2024 European Commission decision.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Vabysmo.
Unlock full calendar →Roche pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
